In a new commentary by leaders in the field, the National Fragile X Foundation (NFXF) announced best practices for fragile X syndrome therapy development to improve the transition of treatments to human patients. The article, “Best Practices in Fragile X Syndrome Treatment Development,”…
News
Mice with the genetic defect that causes fragile X syndrome (FXS) are unable to learn new information that contradicts what they initially learned, researchers at NYU and the State University of New York report. The study, “Control of recollection by slow gamma dominating mid-frequency gamma…
This week marks the launch of the “7,000 Mile Rare Movement,” a nationwide effort to raise money for research into the 7,000 known rare diseases that afflict at least 30 million Americans. The campaign kicks off Feb. 1 and culminates with Rare Disease Day on Feb. 28. Organized by…
The intellectual disabilities in people with fragile X syndrome may be caused by poor communication between neurons, rather than flaws in the nerve cells, according to research from New York University. A research team there discovered that groups of neurons failed to signal in unison when mice with the…
Strategies to Promote Mindfulness, Acceptance Can Benefit Mothers of Fragile X Children, Study Shows
Interventions focused on improving mindfulness and acceptance may promote the health and well-being of mothers who have children with fragile X syndrome (FXS), as well as having important health implications for all individuals with an FMR1 premutation, a study finds. The study, “Mindfulness and Acceptance…
Children with the FMR1 premutation experience difficulties in processing sensory information, similar to those experienced by children with fragile x syndrome, a study shows. The study, “Sensory Difficulties in Children With an FMR1 Premutation,” was published in the journal Frontiers in Genetics. Fragile x syndrome (FXS) is caused…
Recent Posts
- Advocates aim to answer the question ‘Fragile what?’ this awareness month
- Fragile X drug zatolmilast misses main goal in Phase 3 trials
- Targeting star-shaped brain cells reduces fragile X seizures in mice: Study
- Marvel planning trial to test fragile X treatment in healthy volunteers
- FRAXA backs upcoming Phase 2b trial of SPG601 for fragile X syndrome
- Daily use of diabetes drug metformin eases hyperactivity in fragile X boys
- USC researchers net $6.3M federal grant to study fragile X mutations
- 1st patient enrolled in Phase 2 trial of treatment for fragile X syndrome
- Phase 2 trial of experimental oral treatment enrolling fragile X males
- SPG601 calms brain activity in men with fragile X, helping them to focus